Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $115
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
Citi Remains a Buy on Gilead Sciences (GILD)
Gilead Sciences Is Maintained at Outperform by Oppenheimer
Gilead Sciences Analyst Ratings
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $115
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Legend Biotech (LEGN) and Gilead Sciences (GILD)
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Gilead Sciences Receives 'Buy' Rating Amid Strong HIV Market Position and Promising Future Prospects
Piper Sandler Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD)
Gilead Sciences Price Target Raised to $96.00/Share From $70.00 by UBS
UBS Initiates Gilead Sciences(GILD.US) With Hold Rating, Announces Target Price $96
Gilead Sciences Is Maintained at Outperform by Mizuho
Gilead Sciences Analyst Ratings
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $100
Mizuho Securities Adjusts Price Target on Gilead Sciences to $100 From $90
Argus Research Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $100